Skip to main content
Clinical Trials/NCT04239690
NCT04239690
Completed
N/A

A Randomised Controlled Intervention, Multi-centre Study Aiming to Preserve Blood Factors Using Micro-methods to Improve Development in Extremely Preterm Infants - "Less is More"

David Ley1 site in 1 country201 target enrollmentMarch 15, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Bronchopulmonary Dysplasia
Sponsor
David Ley
Enrollment
201
Locations
1
Primary Endpoint
Broncho-pulmonary dysplasia
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

Current clinical protocols for blood sampling and analyses in extremely preterm infants rely on an infrastructure adapted to and developed for adult medicine. Excessive blood sampling volumes and the resulting loss of fetal blood components are related to neonatal morbidity. This randomised trial aims to provide evidence that preservation of blood using micro-methods results in decreased morbidity and increased quality of life in extremely preterm infants.

Detailed Description

Extremely preterm (EPT) infants are subjected to a sample-related withdrawal of whole blood of 50 % of total blood volume during the first 2 postnatal weeks and a transfused volume of 100 % of total blood volume with donor blood during the corresponding time period. The resulting decrease in the proportion of fetal hemoglobin is strongly associated with morbidity outcome, especially broncho-pulmonary dysplasia (BPD), in the EPT infant. This randomized trial evaluates if a reduction in sample-related blood volume loss by 50% during the first two postnatal weeks leads to a reduced rate of BPD in EPT infants. Half of the included infants will be subjected to clinical blood sampling using micromethods during the first two postnatal weeks whereas blood sampling in the other half of infants will be performed using standard clinical methods.

Registry
clinicaltrials.gov
Start Date
March 15, 2020
End Date
July 15, 2024
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
David Ley
Responsible Party
Sponsor Investigator
Principal Investigator

David Ley

Professor

Lund University

Eligibility Criteria

Inclusion Criteria

  • gestational age \< 27 weeks at birth

Exclusion Criteria

  • major malformation

Outcomes

Primary Outcomes

Broncho-pulmonary dysplasia

Time Frame: Broncho-pulmonary dysplasia is determined at a postmenstrual age of 36 weeks

Requirement of supplemental oxygen as determined by the oxygen challenge test

Secondary Outcomes

  • Blood transfusions(Blood transfusions administered during the first two postnatal weeks)
  • Necrotizing enterocolitis(From birth until 40 weeks postmenstrual age)
  • Fetal Hemoglobin(% of fetal hemoglobin at 7 and 14 postnatal days)
  • Cerebral intraventricular haemorrhage(Ultrasound at postnatal day 3, 7, 21 and 40 weeks postmenstrual age)

Study Sites (1)

Loading locations...

Similar Trials